Research ArticleArticle
Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: Outcomes of Importance for Patients with PMR
Sarah L. Mackie, Seher Arat, Jose da Silva, Catia Duarte, Sue Halliday, Rod Hughes, Marianne Morris, Colin T. Pease, Jeffrey W. Sherman, Lee S. Simon, Maggie Walsh, René Westhovens, Samy Zakout and John R. Kirwan
The Journal of Rheumatology February 2014, jrheum.131254; DOI: https://doi.org/10.3899/jrheum.131254
Sarah L. Mackie
From UK National Institute for Health Research (NIHR)-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Polymyalgia Rheumatica Giant Cell Arteritis (PMRGCA) UK, Bristol; Department of Rheumatology Ashford and St Peter’s Hospitals National Health Service (NHS) Foundation Trust, Chertsey, Surrey; Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England, Bristol; Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Horizon Pharma Inc., Deerfield, Illinois; SDG LLC, Boston, Massachusetts, USA; Department of Rheumatology, Katholieke Universiteit Leuven, Leuven, Belgium; Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary, Bristol, UK. S.L. Mackie, BM, BCh, PhD, NIHR-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; S. Arat, RN, MSc, Department of Rheumatology, University Hospitals Leuven; J. da Silva; C. Duarte, Rheumatology Department, Centro Hospitalar e Universitário de Coimbra; S. Halliday, PMRGCA UK; R. Hughes, MA, MD, FRCP, Department of Rheumatology Ashford and St Peter’s Hospitals NHS Foundation Trust; M. Morris, PhD, Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England; C.T. Pease, MD, FRCP, Department of Rheumatology, Leeds Teaching Hospitals NHS Trust; J.W. Sherman, MD, FACP, Chief Medical Officer, Horizon Pharma; L.S. Simon, MD, SDG LLC; M. Walsh, Department of Rheumatology, Ashford and St Peter’s Hospitals NHS Foundation Trust; R. Westhovens, Department of Rheumatology, Katholieke Universiteit Leuven; S. Zakout; J.R. Kirwan, Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary. Address correspondence to Dr. J. Kirwan, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, BS2 8HW, UK. E-mail: john.kirwan@bristol.ac.uk
Seher Arat
From UK National Institute for Health Research (NIHR)-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Polymyalgia Rheumatica Giant Cell Arteritis (PMRGCA) UK, Bristol; Department of Rheumatology Ashford and St Peter’s Hospitals National Health Service (NHS) Foundation Trust, Chertsey, Surrey; Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England, Bristol; Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Horizon Pharma Inc., Deerfield, Illinois; SDG LLC, Boston, Massachusetts, USA; Department of Rheumatology, Katholieke Universiteit Leuven, Leuven, Belgium; Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary, Bristol, UK. S.L. Mackie, BM, BCh, PhD, NIHR-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; S. Arat, RN, MSc, Department of Rheumatology, University Hospitals Leuven; J. da Silva; C. Duarte, Rheumatology Department, Centro Hospitalar e Universitário de Coimbra; S. Halliday, PMRGCA UK; R. Hughes, MA, MD, FRCP, Department of Rheumatology Ashford and St Peter’s Hospitals NHS Foundation Trust; M. Morris, PhD, Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England; C.T. Pease, MD, FRCP, Department of Rheumatology, Leeds Teaching Hospitals NHS Trust; J.W. Sherman, MD, FACP, Chief Medical Officer, Horizon Pharma; L.S. Simon, MD, SDG LLC; M. Walsh, Department of Rheumatology, Ashford and St Peter’s Hospitals NHS Foundation Trust; R. Westhovens, Department of Rheumatology, Katholieke Universiteit Leuven; S. Zakout; J.R. Kirwan, Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary. Address correspondence to Dr. J. Kirwan, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, BS2 8HW, UK. E-mail: john.kirwan@bristol.ac.uk
Jose da Silva
From UK National Institute for Health Research (NIHR)-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Polymyalgia Rheumatica Giant Cell Arteritis (PMRGCA) UK, Bristol; Department of Rheumatology Ashford and St Peter’s Hospitals National Health Service (NHS) Foundation Trust, Chertsey, Surrey; Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England, Bristol; Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Horizon Pharma Inc., Deerfield, Illinois; SDG LLC, Boston, Massachusetts, USA; Department of Rheumatology, Katholieke Universiteit Leuven, Leuven, Belgium; Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary, Bristol, UK. S.L. Mackie, BM, BCh, PhD, NIHR-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; S. Arat, RN, MSc, Department of Rheumatology, University Hospitals Leuven; J. da Silva; C. Duarte, Rheumatology Department, Centro Hospitalar e Universitário de Coimbra; S. Halliday, PMRGCA UK; R. Hughes, MA, MD, FRCP, Department of Rheumatology Ashford and St Peter’s Hospitals NHS Foundation Trust; M. Morris, PhD, Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England; C.T. Pease, MD, FRCP, Department of Rheumatology, Leeds Teaching Hospitals NHS Trust; J.W. Sherman, MD, FACP, Chief Medical Officer, Horizon Pharma; L.S. Simon, MD, SDG LLC; M. Walsh, Department of Rheumatology, Ashford and St Peter’s Hospitals NHS Foundation Trust; R. Westhovens, Department of Rheumatology, Katholieke Universiteit Leuven; S. Zakout; J.R. Kirwan, Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary. Address correspondence to Dr. J. Kirwan, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, BS2 8HW, UK. E-mail: john.kirwan@bristol.ac.uk
Catia Duarte
From UK National Institute for Health Research (NIHR)-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Polymyalgia Rheumatica Giant Cell Arteritis (PMRGCA) UK, Bristol; Department of Rheumatology Ashford and St Peter’s Hospitals National Health Service (NHS) Foundation Trust, Chertsey, Surrey; Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England, Bristol; Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Horizon Pharma Inc., Deerfield, Illinois; SDG LLC, Boston, Massachusetts, USA; Department of Rheumatology, Katholieke Universiteit Leuven, Leuven, Belgium; Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary, Bristol, UK. S.L. Mackie, BM, BCh, PhD, NIHR-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; S. Arat, RN, MSc, Department of Rheumatology, University Hospitals Leuven; J. da Silva; C. Duarte, Rheumatology Department, Centro Hospitalar e Universitário de Coimbra; S. Halliday, PMRGCA UK; R. Hughes, MA, MD, FRCP, Department of Rheumatology Ashford and St Peter’s Hospitals NHS Foundation Trust; M. Morris, PhD, Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England; C.T. Pease, MD, FRCP, Department of Rheumatology, Leeds Teaching Hospitals NHS Trust; J.W. Sherman, MD, FACP, Chief Medical Officer, Horizon Pharma; L.S. Simon, MD, SDG LLC; M. Walsh, Department of Rheumatology, Ashford and St Peter’s Hospitals NHS Foundation Trust; R. Westhovens, Department of Rheumatology, Katholieke Universiteit Leuven; S. Zakout; J.R. Kirwan, Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary. Address correspondence to Dr. J. Kirwan, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, BS2 8HW, UK. E-mail: john.kirwan@bristol.ac.uk
Sue Halliday
From UK National Institute for Health Research (NIHR)-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Polymyalgia Rheumatica Giant Cell Arteritis (PMRGCA) UK, Bristol; Department of Rheumatology Ashford and St Peter’s Hospitals National Health Service (NHS) Foundation Trust, Chertsey, Surrey; Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England, Bristol; Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Horizon Pharma Inc., Deerfield, Illinois; SDG LLC, Boston, Massachusetts, USA; Department of Rheumatology, Katholieke Universiteit Leuven, Leuven, Belgium; Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary, Bristol, UK. S.L. Mackie, BM, BCh, PhD, NIHR-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; S. Arat, RN, MSc, Department of Rheumatology, University Hospitals Leuven; J. da Silva; C. Duarte, Rheumatology Department, Centro Hospitalar e Universitário de Coimbra; S. Halliday, PMRGCA UK; R. Hughes, MA, MD, FRCP, Department of Rheumatology Ashford and St Peter’s Hospitals NHS Foundation Trust; M. Morris, PhD, Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England; C.T. Pease, MD, FRCP, Department of Rheumatology, Leeds Teaching Hospitals NHS Trust; J.W. Sherman, MD, FACP, Chief Medical Officer, Horizon Pharma; L.S. Simon, MD, SDG LLC; M. Walsh, Department of Rheumatology, Ashford and St Peter’s Hospitals NHS Foundation Trust; R. Westhovens, Department of Rheumatology, Katholieke Universiteit Leuven; S. Zakout; J.R. Kirwan, Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary. Address correspondence to Dr. J. Kirwan, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, BS2 8HW, UK. E-mail: john.kirwan@bristol.ac.uk
Rod Hughes
From UK National Institute for Health Research (NIHR)-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Polymyalgia Rheumatica Giant Cell Arteritis (PMRGCA) UK, Bristol; Department of Rheumatology Ashford and St Peter’s Hospitals National Health Service (NHS) Foundation Trust, Chertsey, Surrey; Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England, Bristol; Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Horizon Pharma Inc., Deerfield, Illinois; SDG LLC, Boston, Massachusetts, USA; Department of Rheumatology, Katholieke Universiteit Leuven, Leuven, Belgium; Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary, Bristol, UK. S.L. Mackie, BM, BCh, PhD, NIHR-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; S. Arat, RN, MSc, Department of Rheumatology, University Hospitals Leuven; J. da Silva; C. Duarte, Rheumatology Department, Centro Hospitalar e Universitário de Coimbra; S. Halliday, PMRGCA UK; R. Hughes, MA, MD, FRCP, Department of Rheumatology Ashford and St Peter’s Hospitals NHS Foundation Trust; M. Morris, PhD, Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England; C.T. Pease, MD, FRCP, Department of Rheumatology, Leeds Teaching Hospitals NHS Trust; J.W. Sherman, MD, FACP, Chief Medical Officer, Horizon Pharma; L.S. Simon, MD, SDG LLC; M. Walsh, Department of Rheumatology, Ashford and St Peter’s Hospitals NHS Foundation Trust; R. Westhovens, Department of Rheumatology, Katholieke Universiteit Leuven; S. Zakout; J.R. Kirwan, Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary. Address correspondence to Dr. J. Kirwan, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, BS2 8HW, UK. E-mail: john.kirwan@bristol.ac.uk
Marianne Morris
From UK National Institute for Health Research (NIHR)-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Polymyalgia Rheumatica Giant Cell Arteritis (PMRGCA) UK, Bristol; Department of Rheumatology Ashford and St Peter’s Hospitals National Health Service (NHS) Foundation Trust, Chertsey, Surrey; Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England, Bristol; Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Horizon Pharma Inc., Deerfield, Illinois; SDG LLC, Boston, Massachusetts, USA; Department of Rheumatology, Katholieke Universiteit Leuven, Leuven, Belgium; Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary, Bristol, UK. S.L. Mackie, BM, BCh, PhD, NIHR-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; S. Arat, RN, MSc, Department of Rheumatology, University Hospitals Leuven; J. da Silva; C. Duarte, Rheumatology Department, Centro Hospitalar e Universitário de Coimbra; S. Halliday, PMRGCA UK; R. Hughes, MA, MD, FRCP, Department of Rheumatology Ashford and St Peter’s Hospitals NHS Foundation Trust; M. Morris, PhD, Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England; C.T. Pease, MD, FRCP, Department of Rheumatology, Leeds Teaching Hospitals NHS Trust; J.W. Sherman, MD, FACP, Chief Medical Officer, Horizon Pharma; L.S. Simon, MD, SDG LLC; M. Walsh, Department of Rheumatology, Ashford and St Peter’s Hospitals NHS Foundation Trust; R. Westhovens, Department of Rheumatology, Katholieke Universiteit Leuven; S. Zakout; J.R. Kirwan, Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary. Address correspondence to Dr. J. Kirwan, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, BS2 8HW, UK. E-mail: john.kirwan@bristol.ac.uk
Colin T. Pease
From UK National Institute for Health Research (NIHR)-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Polymyalgia Rheumatica Giant Cell Arteritis (PMRGCA) UK, Bristol; Department of Rheumatology Ashford and St Peter’s Hospitals National Health Service (NHS) Foundation Trust, Chertsey, Surrey; Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England, Bristol; Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Horizon Pharma Inc., Deerfield, Illinois; SDG LLC, Boston, Massachusetts, USA; Department of Rheumatology, Katholieke Universiteit Leuven, Leuven, Belgium; Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary, Bristol, UK. S.L. Mackie, BM, BCh, PhD, NIHR-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; S. Arat, RN, MSc, Department of Rheumatology, University Hospitals Leuven; J. da Silva; C. Duarte, Rheumatology Department, Centro Hospitalar e Universitário de Coimbra; S. Halliday, PMRGCA UK; R. Hughes, MA, MD, FRCP, Department of Rheumatology Ashford and St Peter’s Hospitals NHS Foundation Trust; M. Morris, PhD, Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England; C.T. Pease, MD, FRCP, Department of Rheumatology, Leeds Teaching Hospitals NHS Trust; J.W. Sherman, MD, FACP, Chief Medical Officer, Horizon Pharma; L.S. Simon, MD, SDG LLC; M. Walsh, Department of Rheumatology, Ashford and St Peter’s Hospitals NHS Foundation Trust; R. Westhovens, Department of Rheumatology, Katholieke Universiteit Leuven; S. Zakout; J.R. Kirwan, Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary. Address correspondence to Dr. J. Kirwan, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, BS2 8HW, UK. E-mail: john.kirwan@bristol.ac.uk
Jeffrey W. Sherman
From UK National Institute for Health Research (NIHR)-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Polymyalgia Rheumatica Giant Cell Arteritis (PMRGCA) UK, Bristol; Department of Rheumatology Ashford and St Peter’s Hospitals National Health Service (NHS) Foundation Trust, Chertsey, Surrey; Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England, Bristol; Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Horizon Pharma Inc., Deerfield, Illinois; SDG LLC, Boston, Massachusetts, USA; Department of Rheumatology, Katholieke Universiteit Leuven, Leuven, Belgium; Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary, Bristol, UK. S.L. Mackie, BM, BCh, PhD, NIHR-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; S. Arat, RN, MSc, Department of Rheumatology, University Hospitals Leuven; J. da Silva; C. Duarte, Rheumatology Department, Centro Hospitalar e Universitário de Coimbra; S. Halliday, PMRGCA UK; R. Hughes, MA, MD, FRCP, Department of Rheumatology Ashford and St Peter’s Hospitals NHS Foundation Trust; M. Morris, PhD, Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England; C.T. Pease, MD, FRCP, Department of Rheumatology, Leeds Teaching Hospitals NHS Trust; J.W. Sherman, MD, FACP, Chief Medical Officer, Horizon Pharma; L.S. Simon, MD, SDG LLC; M. Walsh, Department of Rheumatology, Ashford and St Peter’s Hospitals NHS Foundation Trust; R. Westhovens, Department of Rheumatology, Katholieke Universiteit Leuven; S. Zakout; J.R. Kirwan, Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary. Address correspondence to Dr. J. Kirwan, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, BS2 8HW, UK. E-mail: john.kirwan@bristol.ac.uk
Lee S. Simon
From UK National Institute for Health Research (NIHR)-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Polymyalgia Rheumatica Giant Cell Arteritis (PMRGCA) UK, Bristol; Department of Rheumatology Ashford and St Peter’s Hospitals National Health Service (NHS) Foundation Trust, Chertsey, Surrey; Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England, Bristol; Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Horizon Pharma Inc., Deerfield, Illinois; SDG LLC, Boston, Massachusetts, USA; Department of Rheumatology, Katholieke Universiteit Leuven, Leuven, Belgium; Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary, Bristol, UK. S.L. Mackie, BM, BCh, PhD, NIHR-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; S. Arat, RN, MSc, Department of Rheumatology, University Hospitals Leuven; J. da Silva; C. Duarte, Rheumatology Department, Centro Hospitalar e Universitário de Coimbra; S. Halliday, PMRGCA UK; R. Hughes, MA, MD, FRCP, Department of Rheumatology Ashford and St Peter’s Hospitals NHS Foundation Trust; M. Morris, PhD, Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England; C.T. Pease, MD, FRCP, Department of Rheumatology, Leeds Teaching Hospitals NHS Trust; J.W. Sherman, MD, FACP, Chief Medical Officer, Horizon Pharma; L.S. Simon, MD, SDG LLC; M. Walsh, Department of Rheumatology, Ashford and St Peter’s Hospitals NHS Foundation Trust; R. Westhovens, Department of Rheumatology, Katholieke Universiteit Leuven; S. Zakout; J.R. Kirwan, Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary. Address correspondence to Dr. J. Kirwan, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, BS2 8HW, UK. E-mail: john.kirwan@bristol.ac.uk
Maggie Walsh
From UK National Institute for Health Research (NIHR)-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Polymyalgia Rheumatica Giant Cell Arteritis (PMRGCA) UK, Bristol; Department of Rheumatology Ashford and St Peter’s Hospitals National Health Service (NHS) Foundation Trust, Chertsey, Surrey; Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England, Bristol; Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Horizon Pharma Inc., Deerfield, Illinois; SDG LLC, Boston, Massachusetts, USA; Department of Rheumatology, Katholieke Universiteit Leuven, Leuven, Belgium; Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary, Bristol, UK. S.L. Mackie, BM, BCh, PhD, NIHR-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; S. Arat, RN, MSc, Department of Rheumatology, University Hospitals Leuven; J. da Silva; C. Duarte, Rheumatology Department, Centro Hospitalar e Universitário de Coimbra; S. Halliday, PMRGCA UK; R. Hughes, MA, MD, FRCP, Department of Rheumatology Ashford and St Peter’s Hospitals NHS Foundation Trust; M. Morris, PhD, Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England; C.T. Pease, MD, FRCP, Department of Rheumatology, Leeds Teaching Hospitals NHS Trust; J.W. Sherman, MD, FACP, Chief Medical Officer, Horizon Pharma; L.S. Simon, MD, SDG LLC; M. Walsh, Department of Rheumatology, Ashford and St Peter’s Hospitals NHS Foundation Trust; R. Westhovens, Department of Rheumatology, Katholieke Universiteit Leuven; S. Zakout; J.R. Kirwan, Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary. Address correspondence to Dr. J. Kirwan, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, BS2 8HW, UK. E-mail: john.kirwan@bristol.ac.uk
René Westhovens
From UK National Institute for Health Research (NIHR)-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Polymyalgia Rheumatica Giant Cell Arteritis (PMRGCA) UK, Bristol; Department of Rheumatology Ashford and St Peter’s Hospitals National Health Service (NHS) Foundation Trust, Chertsey, Surrey; Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England, Bristol; Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Horizon Pharma Inc., Deerfield, Illinois; SDG LLC, Boston, Massachusetts, USA; Department of Rheumatology, Katholieke Universiteit Leuven, Leuven, Belgium; Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary, Bristol, UK. S.L. Mackie, BM, BCh, PhD, NIHR-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; S. Arat, RN, MSc, Department of Rheumatology, University Hospitals Leuven; J. da Silva; C. Duarte, Rheumatology Department, Centro Hospitalar e Universitário de Coimbra; S. Halliday, PMRGCA UK; R. Hughes, MA, MD, FRCP, Department of Rheumatology Ashford and St Peter’s Hospitals NHS Foundation Trust; M. Morris, PhD, Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England; C.T. Pease, MD, FRCP, Department of Rheumatology, Leeds Teaching Hospitals NHS Trust; J.W. Sherman, MD, FACP, Chief Medical Officer, Horizon Pharma; L.S. Simon, MD, SDG LLC; M. Walsh, Department of Rheumatology, Ashford and St Peter’s Hospitals NHS Foundation Trust; R. Westhovens, Department of Rheumatology, Katholieke Universiteit Leuven; S. Zakout; J.R. Kirwan, Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary. Address correspondence to Dr. J. Kirwan, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, BS2 8HW, UK. E-mail: john.kirwan@bristol.ac.uk
Samy Zakout
From UK National Institute for Health Research (NIHR)-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Polymyalgia Rheumatica Giant Cell Arteritis (PMRGCA) UK, Bristol; Department of Rheumatology Ashford and St Peter’s Hospitals National Health Service (NHS) Foundation Trust, Chertsey, Surrey; Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England, Bristol; Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Horizon Pharma Inc., Deerfield, Illinois; SDG LLC, Boston, Massachusetts, USA; Department of Rheumatology, Katholieke Universiteit Leuven, Leuven, Belgium; Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary, Bristol, UK. S.L. Mackie, BM, BCh, PhD, NIHR-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; S. Arat, RN, MSc, Department of Rheumatology, University Hospitals Leuven; J. da Silva; C. Duarte, Rheumatology Department, Centro Hospitalar e Universitário de Coimbra; S. Halliday, PMRGCA UK; R. Hughes, MA, MD, FRCP, Department of Rheumatology Ashford and St Peter’s Hospitals NHS Foundation Trust; M. Morris, PhD, Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England; C.T. Pease, MD, FRCP, Department of Rheumatology, Leeds Teaching Hospitals NHS Trust; J.W. Sherman, MD, FACP, Chief Medical Officer, Horizon Pharma; L.S. Simon, MD, SDG LLC; M. Walsh, Department of Rheumatology, Ashford and St Peter’s Hospitals NHS Foundation Trust; R. Westhovens, Department of Rheumatology, Katholieke Universiteit Leuven; S. Zakout; J.R. Kirwan, Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary. Address correspondence to Dr. J. Kirwan, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, BS2 8HW, UK. E-mail: john.kirwan@bristol.ac.uk
John R. Kirwan
From UK National Institute for Health Research (NIHR)-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Polymyalgia Rheumatica Giant Cell Arteritis (PMRGCA) UK, Bristol; Department of Rheumatology Ashford and St Peter’s Hospitals National Health Service (NHS) Foundation Trust, Chertsey, Surrey; Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England, Bristol; Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Horizon Pharma Inc., Deerfield, Illinois; SDG LLC, Boston, Massachusetts, USA; Department of Rheumatology, Katholieke Universiteit Leuven, Leuven, Belgium; Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary, Bristol, UK. S.L. Mackie, BM, BCh, PhD, NIHR-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; S. Arat, RN, MSc, Department of Rheumatology, University Hospitals Leuven; J. da Silva; C. Duarte, Rheumatology Department, Centro Hospitalar e Universitário de Coimbra; S. Halliday, PMRGCA UK; R. Hughes, MA, MD, FRCP, Department of Rheumatology Ashford and St Peter’s Hospitals NHS Foundation Trust; M. Morris, PhD, Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England; C.T. Pease, MD, FRCP, Department of Rheumatology, Leeds Teaching Hospitals NHS Trust; J.W. Sherman, MD, FACP, Chief Medical Officer, Horizon Pharma; L.S. Simon, MD, SDG LLC; M. Walsh, Department of Rheumatology, Ashford and St Peter’s Hospitals NHS Foundation Trust; R. Westhovens, Department of Rheumatology, Katholieke Universiteit Leuven; S. Zakout; J.R. Kirwan, Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary. Address correspondence to Dr. J. Kirwan, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, BS2 8HW, UK. E-mail: john.kirwan@bristol.ac.uk
Article Information
jrheum.131254
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online February 1, 2014.
Article Versions
- You are currently viewing a Latest version of this article (February 1, 2014 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2014 The Journal of Rheumatology
Author Information
- Sarah L. Mackie,
- Seher Arat,
- Jose da Silva,
- Catia Duarte,
- Sue Halliday,
- Rod Hughes,
- Marianne Morris,
- Colin T. Pease,
- Jeffrey W. Sherman,
- Lee S. Simon,
- Maggie Walsh,
- René Westhovens,
- Samy Zakout and
- John R. Kirwan
- From UK National Institute for Health Research (NIHR)-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Polymyalgia Rheumatica Giant Cell Arteritis (PMRGCA) UK, Bristol; Department of Rheumatology Ashford and St Peter’s Hospitals National Health Service (NHS) Foundation Trust, Chertsey, Surrey; Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England, Bristol; Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Horizon Pharma Inc., Deerfield, Illinois; SDG LLC, Boston, Massachusetts, USA; Department of Rheumatology, Katholieke Universiteit Leuven, Leuven, Belgium; Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary, Bristol, UK. S.L. Mackie, BM, BCh, PhD, NIHR-Leeds Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; S. Arat, RN, MSc, Department of Rheumatology, University Hospitals Leuven; J. da Silva; C. Duarte, Rheumatology Department, Centro Hospitalar e Universitário de Coimbra; S. Halliday, PMRGCA UK; R. Hughes, MA, MD, FRCP, Department of Rheumatology Ashford and St Peter’s Hospitals NHS Foundation Trust; M. Morris, PhD, Centre for Health and Clinical Research, Faculty of Health and Life Sciences, University of the West of England; C.T. Pease, MD, FRCP, Department of Rheumatology, Leeds Teaching Hospitals NHS Trust; J.W. Sherman, MD, FACP, Chief Medical Officer, Horizon Pharma; L.S. Simon, MD, SDG LLC; M. Walsh, Department of Rheumatology, Ashford and St Peter’s Hospitals NHS Foundation Trust; R. Westhovens, Department of Rheumatology, Katholieke Universiteit Leuven; S. Zakout; J.R. Kirwan, Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary.
Address correspondence to Dr. J. Kirwan, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, BS2 8HW, UK. E-mail: john.kirwan@bristol.ac.uk
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: Outcomes of Importance for Patients with PMR
Sarah L. Mackie, Seher Arat, Jose da Silva, Catia Duarte, Sue Halliday, Rod Hughes, Marianne Morris, Colin T. Pease, Jeffrey W. Sherman, Lee S. Simon, Maggie Walsh, René Westhovens, Samy Zakout, John R. Kirwan
The Journal of Rheumatology Feb 2014, jrheum.131254; DOI: 10.3899/jrheum.131254
Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: Outcomes of Importance for Patients with PMR
Sarah L. Mackie, Seher Arat, Jose da Silva, Catia Duarte, Sue Halliday, Rod Hughes, Marianne Morris, Colin T. Pease, Jeffrey W. Sherman, Lee S. Simon, Maggie Walsh, René Westhovens, Samy Zakout, John R. Kirwan
The Journal of Rheumatology Feb 2014, jrheum.131254; DOI: 10.3899/jrheum.131254